CHRNA2 and prostate cancer: Cholinergic receptors (CHRM1 and CHRNA2), homeobox B13 (HOXB13), matrix metallopeptidase 26 (MMP26), NK3 homeobox 1 (NKX3-1), prostate cancer susceptibility candidate (PRAC1 and PRAC2), SAM pointed domain containing ETS transcription factor (SPDEF), transglutaminase 4 (TGM4), and transient receptor potential cation channel subfamily M member 8 (TRPM8) are associated with prostate cancer [92–99].